Clinical Trials

Current Clinical Trials

The COSMO Study: Adherence to Cardio-Oncology Surveillance Recommendations and Cardiotoxicity Outcomes in Patients Receiving Cardiotoxic Antineoplastic Therapies - A Retrospective Case Series
  1. Thomas Schulz, MD
    Thomas Schulz, MD
  2. for people 18 to 110 (full criteria)
  3. Rancho Mirage, CA
  4. study started June 2026
  5. Thomas Schulz, MD
  6. Accepting new patients

Description

Summary

This is a retrospective, case series study using electronic health record (EHR) data. Adult oncology patients exposed to cardiotoxic antineoplastic therapies will be evaluated for adherence to guideline-based cardiovascular surveillance practices and cardiotoxicity-related outcomes.

Official Title

The COSMO Study: Adherence to Cardio-Oncology Surveillance Recommendations and Cardiotoxicity Outcomes in Patients Receiving Cardiotoxic Antineoplastic Therapies - A Retrospective Case Series

Keywords

Adult oncology patients exposed to cardiotoxic antineoplastic therapies

Eligibility

for people 18 to 110
1. Age =18 years  2. Exposure to at least one cardiotoxic antineoplastic therapy  ... more
less

1. Age =18 years  
2. Exposure to at least one cardiotoxic antineoplastic therapy  

Lead Scientist at Eisenhower Health

Thomas Schulz, MD
Thomas Schulz, MD, is Board Certified in Medical Oncology, Hematology and Internal Medicine. He is Medical Director of Eisenhower Hematology/Oncology overseeing five locations. Dr. Schulz sees patients in Rancho Mirage and Yucca Valley. After earning a medical degree and completing an internal medicine residency program at the University of Kansas School of Medicine, he completed fellowship program in hematology and medical oncology at the University of Colorado School of Medicine.Dr. Schulz ini... more
less

Thomas Schulz, MD, is Board Certified in Medical Oncology, Hematology and Internal Medicine. He is Medical Director of Eisenhower Hematology/Oncology overseeing five locations. Dr. Schulz sees patients in Rancho Mirage and Yucca Valley. After earning a medical degree and completing an internal medicine residency program at the University of Kansas School of Medicine, he completed fellowship program in hematology and medical oncology at the University of Colorado School of Medicine.

Dr. Schulz initially became interested in medicine in high school, seeing his mother battle metastatic breast cancer. While in medical school and residency, he had a difficult time deciding on a specialty. “I liked every rotation,” states Dr. Schulz. “But I always came back to oncology – it was the patients who were so special. I was drawn toward my desire to come alongside of very ill patients and help to make their journey in the health system better.” While Dr. Schulz sees all types of cancer patients, his practices focuses on benign hematology including anemias, iron deficiency, bleeding disorders and thromboembolic disease.

When interacting with patients, Dr. Schulz focuses on compassion. “Everyone is someone’s daughter or son,” he comments. “I find compassionate listening is a key tool as I find useful information when I understand my patient’s story and their lifestyle needs.

 

 
 

Clinical Study Details

  1. Accepting new patients
  2. study started June 2026
  3. Retrospective Case Series
  4. October 01, 2026
Cookie Disclaimer:

By using or otherwise accessing the website, you agree to that this website uses cookies and similar technologies, including those provided by vendors, for various purposes, such as to support website performance, features, and analytics (for example, Google Analytics). These cookies may process data such as IP addresses, including for them to function properly. Cookie vary across the website, including per webpage. For more information, see the Website Privacy Policy. Use or other access to this website is subject to the Website Terms and Conditions.

Accept ALL cookies to enhance your experience, including analytics that help us understand how our site is used. Accept Required allows only essential cookies needed for the website to function, such as session management and your cookie preferences. Accept None does not allow any non-essential cookies and no cookies are stored after your session is complete. Modify My Preferences